1. Economic analysis of allogeneic hematopoietic stem cell transplantation in the Bone Marrow Transplant Center of Tunisia
- Author
-
Leila Achour, Chema Drira, Mohamed Zied Sboui, Ikram Fazaa, Mohamed Ali Soussi, Senda Hammami, Tarek Ben Othman, and Myriam Razgallah Khrouf
- Subjects
Costs ,allogeneic hematopoietic cell transplantation ,bone marrow transplantation ,peripheral blood stem cell transplantation ,Public aspects of medicine ,RA1-1270 ,Business ,HF5001-6182 - Abstract
ABSTRACTIntroduction: New procedures and diagnostic tests in hematopoietic stem cell transplantation (HSCT) are associated with a significant increase in costs. The last cost estimate of allogeneic HSCT done in Tunisia was in 1996 and concerned only direct medical costs. Therefore, an updated cost analysis is needed.Objective: Analysis of direct costs during the first-year post-allogeneic HSCT in two groups of patients: Bone Marrow Transplant (Allo-BMT) and Peripheral Blood Stem Cell Transplant (Allo-PBSCT) and identification of factors leading to interindividual variations in costs in order to compare these costs with the budget allocated by the payer (CNAM).Methods: Pharmacoeconomic retrospective study, concerning patients who underwent allogeneic HSCT in 2013. Clinical and unit cost data were obtained from medical and administration records.Results:This study showed that the average direct cost of allogeneic HSCT in the population during the first year reached 56 638€. The average cost of Allo-BMT was 63 612€, and Allo-PBSCT was 45 966€ (p > 0.05). The initial hospitalization counted for 88% of total direct cost with an average cost of 41 441€ in Allo-BMT and 24 672€ in Allo-PBSCT (p
- Published
- 2023
- Full Text
- View/download PDF